Trinity Biotech Q1 Revenue Surges 43%, Gross Margin Up Sharply; Secures 2M HIV Test Orders
TRIB sits 55% above its 52-week low of $0.501 on elevated volume (1.9× avg).
Summary
Trinity Biotech reported strong Q1 2026 financial results, with revenue surging 43% year-over-year to $10.8 million and gross margin significantly improving from 25.2% to 35.4%. The company also announced new orders for over 2 million TrinScreen HIV tests, slated for Q3 2026 fulfillment, which are expected to materially boost 2026 revenue and profitability. This positive operational update follows a period of severe financial distress and highly dilutive financing activities, including recent ATM offerings and debt-to-equity conversions. The improved performance, particularly the margin expansion, suggests progress on its Comprehensive Transformation Plan and offers a crucial counterpoint to recent going concern warnings. The company anticipates further gross margin and cash flow improvements as outsourced UniGold HIV™ production scales up in Q3 2026.
At the time of this announcement, TRIB was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.1M. The 52-week trading range was $0.50 to $3.44. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.